Compare Stocks: AVBP, TVTX, ERAS, and GRFS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$29.57 -1.4%	$31.80	$17.00 ▼ $35.83	$1.39B	1.36	515,433 shs	108,833 shs
ERAS Erasca	$17.78 -0.5%	$17.18	$1.33 ▼ $24.28	$6.20B	0.66	6.22 million shs	577,310 shs
GRFS Grifols	$7.90 -0.4%	$7.53	$6.96 ▼ $10.77	$5.37B	0.67	665,579 shs	61,751 shs
TVTX Travere Therapeutics	$61.35 -0.1%	$56.19	$17.05 ▼ $66.24	$5.78B	1.12	2.10 million shs	195,786 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	-4.64%	-3.26%	-7.81%	+7.64%	+66.48%
ERAS Erasca	-3.88%	-2.24%	-8.41%	+74.58%	+1,002.47%
GRFS Grifols	0.00%	+1.28%	+12.96%	+3.52%	-25.47%
TVTX Travere Therapeutics	-1.17%	-1.63%	+7.66%	+44.24%	+240.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$29.57 -1.4%	$31.80	$17.00 ▼ $35.83	$1.39B	1.36	515,433 shs	108,833 shs
ERAS Erasca	$17.78 -0.5%	$17.18	$1.33 ▼ $24.28	$6.20B	0.66	6.22 million shs	577,310 shs
GRFS Grifols	$7.90 -0.4%	$7.53	$6.96 ▼ $10.77	$5.37B	0.67	665,579 shs	61,751 shs
TVTX Travere Therapeutics	$61.35 -0.1%	$56.19	$17.05 ▼ $66.24	$5.78B	1.12	2.10 million shs	195,786 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	-4.64%	-3.26%	-7.81%	+7.64%	+66.48%
ERAS Erasca	-3.88%	-2.24%	-8.41%	+74.58%	+1,002.47%
GRFS Grifols	0.00%	+1.28%	+12.96%	+3.52%	-25.47%
TVTX Travere Therapeutics	-1.17%	-1.63%	+7.66%	+44.24%	+240.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	2.70	Moderate Buy	$44.43	50.25% Upside
ERAS Erasca	2.64	Moderate Buy	$21.91	23.24% Upside
GRFS Grifols	1.67	Reduce	$10.00	26.66% Upside
TVTX Travere Therapeutics	2.69	Moderate Buy	$61.67	0.51% Upside

Current Analyst Ratings Breakdown

Latest AVBP, TVTX, ERAS, and GRFS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	ERAS Erasca	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $21.00
8/13/2026	AVBP ArriVent BioPharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$43.00 ➝ $40.00
8/13/2026	AVBP ArriVent BioPharma	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$45.00
8/13/2026	AVBP ArriVent BioPharma	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$42.00
8/12/2026	ERAS Erasca	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $22.00
8/10/2026	TVTX Travere Therapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$78.00
8/6/2026	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$61.00 ➝ $75.00
8/6/2026	TVTX Travere Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$62.00 ➝ $70.00
8/5/2026	TVTX Travere Therapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/5/2026	TVTX Travere Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$65.00 ➝ $75.00
8/5/2026	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$70.00 ➝ $85.00

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$7.44 per share	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	$1.05 per share	N/A
GRFS Grifols	$7.42B	0.72	$1.41 per share	5.60	$13.63 per share	0.58
TVTX Travere Therapeutics	$490.73M	11.78	$0.36 per share	171.65	$0.26 per share	235.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$166.31M	-$3.47	N/A	N/A	N/A	N/A	-52.47%	-48.68%	8/14/2026 (Estimated)
ERAS Erasca	-$124.55M	-$0.95	N/A	N/A	N/A	N/A	-38.60%	-32.22%	N/A
GRFS Grifols	$454.82M	$0.19	41.55	6.03	0.29	5.54%	6.21%	2.39%	N/A
TVTX Travere Therapeutics	-$25.55M	-$0.46	N/A	23.33	N/A	-7.35%	-55.15%	-6.88%	10/29/2026 (Estimated)

Latest AVBP, TVTX, ERAS, and GRFS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2026	Q2 2026	AVBP ArriVent BioPharma	-$0.9873	-$1.05	-$0.0627	-$1.05	N/A	N/A
8/12/2026	Q2 2026	ERAS Erasca	-$0.1114	-$0.14	-$0.0286	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
GRFS Grifols	$0.08	1.01%	N/A	42.11%	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest AVBP, TVTX, ERAS, and GRFS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/19/2026	GRFS Grifols	special	$0.0945		7/2/2026	7/2/2026	7/9/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	13.95	13.95
ERAS Erasca	N/A	9.52	9.52
GRFS Grifols	1.10	2.37	0.81
TVTX Travere Therapeutics	24.58	4.05	3.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
ERAS Erasca	67.78%
GRFS Grifols	N/A
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	8.58%
ERAS Erasca	14.20%
GRFS Grifols	0.19%
TVTX Travere Therapeutics	4.44%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	46.58 million	42.58 million	N/A
ERAS Erasca	120	349.76 million	266.83 million	Optionable
GRFS Grifols	25,247	680.58 million	679.28 million	Optionable
TVTX Travere Therapeutics	460	94.26 million	90.08 million	Optionable

AVBP, TVTX, ERAS, and GRFS Headlines

Recent News About These Companies

Bank of America Corp DE Trims Position in Travere Therapeutics, Inc. $TVTX

August 14 at 3:35 AM | marketbeat.com

Q3 EPS Estimate for Travere Therapeutics Lifted by Analyst

August 14 at 1:28 AM | americanbankingnews.com

Travere Therapeutics (TVTX) Q2 2026 Earnings Call Transcript

August 12 at 1:35 PM | finance.yahoo.com

What is HC Wainwright's Estimate for TVTX Q3 Earnings?

August 12 at 6:11 AM | marketbeat.com

Travere Therapeutics, Inc. $TVTX Shares Bought by Quantinno Capital Management LP

August 12 at 4:23 AM | marketbeat.com

California State Teachers Retirement System Increases Stock Holdings in Travere Therapeutics, Inc. $TVTX

August 10, 2026 | marketbeat.com

Assenagon Asset Management S.A. Boosts Stock Holdings in Travere Therapeutics, Inc. $TVTX

August 10, 2026 | marketbeat.com

Hennion & Walsh Asset Management Inc. Raises Holdings in Travere Therapeutics, Inc. $TVTX

August 9, 2026 | marketbeat.com

Wedbush Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

August 8, 2026 | theglobeandmail.com

Why Travere Therapeutics (TVTX) Is Up 9.0% After FILSPARI-Driven Q2 Revenue Jump And Wider Loss

August 7, 2026 | finance.yahoo.com

Travere Therapeutics (TVTX) On Q2 Results And FILSPARI Hopes As Fair Value Stays In View

August 7, 2026 | finance.yahoo.com

Travere Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

Travere Therapeutics Q2 Earnings: Why I'm Downgrading To Hold (Again)

August 6, 2026 | seekingalpha.com

Travere Therapeutics, Inc. $TVTX Shares Acquired by Sei Investments Co.

August 6, 2026 | marketbeat.com

TD Cowen Issues Positive Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price

August 6, 2026 | americanbankingnews.com

Empowered Funds LLC Increases Holdings in Travere Therapeutics, Inc. $TVTX

August 6, 2026 | marketbeat.com

Travere signals potential for more than $3B in peak annual FILSPARI sales as FSGS launch exceeds expectations

August 5, 2026 | seekingalpha.com

Travere Therapeutics (TVTX) stock rallies over 13% after hours: Here's what is going on

August 5, 2026 | msn.com

Travere Therapeutics to Participate at Upcoming Investor Conferences

August 5, 2026 | businesswire.com

Travere Therapeutics (NASDAQ:TVTX) Given New $75.00 Price Target at TD Cowen

August 5, 2026 | marketbeat.com

Travere Therapeutics (NASDAQ:TVTX) Sets New 52-Week High - Here's Why

August 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP, TVTX, ERAS, and GRFS Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$29.57 -0.43 (-1.43%)

As of 11:41 AM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Erasca NASDAQ:ERAS

$17.78 -0.08 (-0.46%)

As of 11:41 AM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Grifols NASDAQ:GRFS

$7.90 -0.04 (-0.44%)

As of 11:40 AM Eastern

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Travere Therapeutics NASDAQ:TVTX

$61.35 -0.08 (-0.12%)

As of 11:41 AM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVBP, TVTX, ERAS, and GRFS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVBP, TVTX, ERAS, and GRFS Earnings

Compare Dividends

Latest AVBP, TVTX, ERAS, and GRFS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVBP, TVTX, ERAS, and GRFS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP, TVTX, ERAS, and GRFS Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

Erasca NASDAQ:ERAS

Grifols NASDAQ:GRFS

Travere Therapeutics NASDAQ:TVTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVBP, TVTX, ERAS, and GRFS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVBP, TVTX, ERAS, and GRFS Earnings

Compare Dividends

Latest AVBP, TVTX, ERAS, and GRFS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVBP, TVTX, ERAS, and GRFS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP, TVTX, ERAS, and GRFS Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

Erasca NASDAQ:ERAS

Grifols NASDAQ:GRFS

Travere Therapeutics NASDAQ:TVTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools